Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials

被引:16
|
作者
Scheuermann, Joshua S. [1 ]
Reddin, Janet S. [1 ]
Opanowski, Adam [2 ]
Kinahan, Paul E. [3 ]
Siegel, Barry A. [4 ,5 ]
Shankar, Lalitha K. [6 ]
Karp, Joel S. [1 ]
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[2] Amer Coll Radiol Imaging Network, Philadelphia, PA USA
[3] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[4] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA
[5] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA
[6] NCI, Canc Imaging Program, Rockville, MD USA
关键词
CQIE; PET qualification; quantitative imaging; STANDARDIZED UPTAKE VALUE; F-18-FDG PET/CT; MULTICENTER TRIALS; FDG-PET/CT; NETWORK; EXPERIENCE; BIOMARKER; VARIANCE; PROTOCOL; THERAPY;
D O I
10.2967/jnumed.116.186759
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The National Cancer Institute developed the Centers for Quantitative Imaging Excellence (CQIE) initiative in 2010 to prequalify imaging facilities at all of the National Cancer Institute-designated comprehensive and clinical cancer centers for oncology trials using advanced imaging techniques, including PET. Here we review the CQIE PET/CT scanner qualification process and results in detail. Methods: Over a period of approximately 5 y, sites were requested to submit a variety of phantoms, including uniform and American College of Radiology-approved phantoms, PET/CT images, and examples of clinical images. Submissions were divided into 3 distinct time periods: initial submission (T0) and 2 requalification submissions (T1 and T2). Images were analyzed using standardized procedures, and scanners received a pass or fail designation. Sites had the opportunity to submit new data for scanners that failed. Quantitative results were compared across scanners within a given time period and across time periods for a given scanner. Results: Data from 65 unique PET/CT scanners across 56 sites were submitted for CQIE T0 qualification; 64 scanners passed the qualification. Data from 44 (68%) of those 65 scanners were submitted for T2. From T0 to T2, the percentage of scanners passing the CQIE qualification on the first attempt rose from 38% for T1 to 67% for T2. The most common reasons for failure were SUV outside specifications, incomplete submission, and uniformity issues. Uniform phantom and American College of Radiology-approved phantom results between scanner manufacturers were similar. Conclusion: The results of the CQIE process showed that periodic requalification may decrease the frequency of deficient data submissions. The CQIE project also highlighted the concern within imaging facilities about the burden of maintaining different qualifications and accreditations. Finally, for quantitative imaging-based trials, further evaluation of the relationships between the level of the qualification (e.g., bias or precision) and the quality of the image data, accrual rates, and study power is needed.
引用
收藏
页码:1065 / 1071
页数:7
相关论文
共 50 条
  • [1] Utilization of National Cancer Institute-Designated Cancer Centers by Medicare Beneficiaries with Cancer
    Erfani, Parsa
    Ojo, Ayotomiwa
    Orav, E. John
    Chino, Fumiko
    Lam, Miranda B.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (12) : 7250 - 7258
  • [2] Utilization of National Cancer Institute-Designated Cancer Centers by Medicare Beneficiaries with Cancer
    Parsa Erfani
    Ayotomiwa Ojo
    E. John Orav
    Fumiko Chino
    Miranda B. Lam
    Annals of Surgical Oncology, 2022, 29 : 7250 - 7258
  • [3] Assessment of Parking Fees at National Cancer Institute-Designated Cancer Treatment Centers
    Lee, Anna
    Shah, Kanan
    Chino, Fumiko
    JAMA ONCOLOGY, 2020, 6 (08) : 1295 - 1297
  • [4] Understanding Thyroidectomy Cost Variations Among National Cancer Institute-Designated Cancer Centers
    Si-Yuan Wu
    John Terrell
    Anne Park
    Nancy Perrier
    World Journal of Surgery, 2020, 44 : 385 - 392
  • [5] Improving the Time to Activation of New Clinical Trials at a National Cancer Institute-Designated Comprehensive Cancer Center
    Williams, Erin
    Brown, Timothy J.
    Griffith, Patrice
    Rahimi, Asal
    Oilepo, Rhonda
    Hammers, Hans
    Laetsch, Theodore W.
    Currykosky, Penny
    Partridge, Susan
    Beg, Muhammad S.
    JCO ONCOLOGY PRACTICE, 2020, 16 (04) : 166 - +
  • [6] Adherence to postresection colorectal cancer surveillance at National Cancer Institute-designated Comprehensive Cancer Centers
    Kupfer, Sonia S.
    Lubner, Sam
    Coronel, Emmanuel
    Pickhardt, Perry J.
    Tipping, Matthew
    Graffy, Peter
    Keenan, Eileen
    Ross, Eric
    Li, Tianyu
    Weinberg, David S.
    CANCER MEDICINE, 2018, 7 (11): : 5351 - 5358
  • [7] State of Integration of Palliative Care at National Cancer Institute-Designated and Nondesignated Cancer Centers
    Hui, David
    De la Rosa, Allison
    Bruera, Eduardo
    JAMA ONCOLOGY, 2020, 6 (08) : 1292 - 1295
  • [8] What Factors Influence Minority Use of National Cancer Institute-Designated Cancer Centers?
    Huang, Lyen C.
    Ma, Yifei
    Ngo, Justine V.
    Rhoads, Kim F.
    CANCER, 2014, 120 (03) : 399 - 407
  • [9] Understanding Thyroidectomy Cost Variations Among National Cancer Institute-Designated Cancer Centers
    Wu, Si-Yuan
    Terrell, John
    Park, Anne
    Perrier, Nancy
    WORLD JOURNAL OF SURGERY, 2020, 44 (02) : 385 - 392
  • [10] Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers
    de Moor, Janet S.
    Mollica, Michelle
    Sampson, Annie
    Adjei, Brenda
    Weaver, Sallie J.
    Geiger, Ann M.
    Kramer, Barnett S.
    Grenen, Emily
    Miscally, Memi
    Ciolino, Henry P.
    JNCI CANCER SPECTRUM, 2021, 5 (03)